{"id":119132,"date":"2021-02-03T09:23:41","date_gmt":"2021-02-03T17:23:41","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/02\/dosing-begins-in-phase-1-trial-of-stem-cell-therapy-for-bradykinesia"},"modified":"2021-02-03T09:23:41","modified_gmt":"2021-02-03T17:23:41","slug":"dosing-begins-in-phase-1-trial-of-stem-cell-therapy-for-bradykinesia","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/02\/dosing-begins-in-phase-1-trial-of-stem-cell-therapy-for-bradykinesia","title":{"rendered":"Dosing Begins in Phase 1 Trial of Stem Cell Therapy for Bradykinesia"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/dosing-begins-in-phase-1-trial-of-stem-cell-therapy-for-bradykinesia.jpg\"><\/a><\/p>\n<p>A first patient has been dosed in <a href=\"https:\/\/ir.imacregeneration.com\/\">IMAC Holdings<\/a>\u2019 Phase 1 clinical trial evaluating its investigational umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment for <a href=\"https:\/\/parkinsonsnewstoday.com\/parkinsons-disease-symptoms\/motor\/bradykinesia\/\">bradykinesia<\/a>, a common motor symptom of <a href=\"https:\/\/parkinsonsnewstoday.com\/what-is-parkinsons-disease\/\">Parkinson\u2019s disease<\/a>.<\/p>\n<p>The infusion treatment was given on Dec. 292020, by the trial\u2019s lead investigator Ricardo Knight, MD, at IMAC\u2019s facility in Brentwood, Tennessee, the company <a href=\"https:\/\/www.globenewswire.com\/news-release\/2020\/12\/30\/2151749\/0\/en\/IMAC-Holdings-Completes-First-Infusion-of-Stem-Cells-in-Clinical-Study-for-the-Treatment-of-Bradykinesia-Due-to-Parkinson-s-Disease.html\">announced<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A first patient has been dosed in IMAC Holdings\u2019 Phase 1 clinical trial evaluating its investigational umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment for bradykinesia, a common motor symptom of Parkinson\u2019s disease. The infusion treatment was given on Dec. 292020, by the trial\u2019s lead investigator Ricardo Knight, MD, at IMAC\u2019s facility in [\u2026]<\/p>\n","protected":false},"author":513,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-119132","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/119132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/513"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=119132"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/119132\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=119132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=119132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=119132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}